New data fortifies Eli Lilly’s standing in the burgeoning market for weight-loss drugs

News Room

Eli Lilly (LLY) bolstered its position in the budding weight-loss drug market after new data showed its oral obesity pill was highly effective in a mid-stage study.

Eli Lilly shares are taking a breather Monday, but we see no reason to join the sellers. Our long-term faith in the Club holding is firmly intact, as the pharmaceuticals giant once again shored up confidence in its quality drug pipeline.

Read the full article here

Share this Article
Leave a comment